Award
NIH Reporter #5P01CA163205-14
Project 4: Awakening immune responses to GBM by enhancing immune cell trafficking and activation with oHSV armed with Cetuximab-CCL5 and anti-CD47 antibody payloads.
Recipient
BRIGHAM AND WOMEN'S HOSPITAL
Award Amount
$354,153.00
Ceiling
$354,153.00
Awarded
September 09, 2026
Identifier
5P01CA163205-14
NIH/NCI awarded a project to develop oncolytic viruses to treat glioblastoma by enhancing immune cell trafficking and activation using oHSV armed with Cetuximab-CCL5 and anti-CD47 antibody payloads.
Description
The project involves developing oncolytic viruses for glioblastoma treatment, including preclinical efficacy and safety studies, funded by the NIH/NCI under grant number 5P01CA163205-14. The project aims to enhance immune responses in the tumor microenvironment.